Resmed (RSMDF) EPS (Basic) (2009 - 2026)

Resmed (RSMDF) has reported EPS (Basic) for 18 consecutive years, with $2.63 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) rose 1.81% year-over-year to $2.63; the trailing twelve-month figure through Jun 2026 stood at $10.47 (up 9.64% YoY), and the FY2026 full-year result was $10.47, up 9.64% from the prior year.
• EPS (Basic) retreated to $2.63 in Q2 2026 per RSMDF's latest filing, from $2.74 in the prior quarter.
• Across five years, EPS (Basic) topped out at $2.74 in Q1 2026 and bottomed at $1.22 in Q1 2022.
• Historically, EPS (Basic) has averaged $1.98 across 5 years, with a median of $2.02 in 2024.
• The sharpest annual moves came in 2022 and 2023: EPS (Basic) jumped 326.96% in 2022, then declined 7.43% in 2023.
• Over 5 years, EPS (Basic) stood at $1.53 in 2022, then slipped by 7.43% to $1.42 in 2023, then surged by 65.41% to $2.35 in 2024, then grew by 14.68% to $2.69 in 2025, then decreased by 2.12% to $2.63 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $2.63, $2.74, and $2.69 for Q2 2026, Q1 2026, and Q4 2025 respectively.